BioCentury | Sep 4, 2008
Targets & Mechanisms

New Sine Qua Non for CMV

...from either an infected transplant or reactivation of latent virus in the patient. Biotest markets Cytotect...
BioCentury | Sep 17, 2007
Company News

Biotest, Nabi deal

...plant, nine U.S. plasma collection centers and NABI's headquarters in Boca Raton, Fla. BIO has Cytotect...
...This quarter, BIO and partner Abbott (ABT) plan to begin a Phase III trial of Cytotect...
...plant, nine U.S. plasma collection centers and NABI's headquarters in Boca Raton, Fla. BIO has Cytotect...
BioCentury | Sep 12, 2007
Company News

Biotest acquiring Nabi's biologics unit

...plant, nine U.S. plasma collection centers and NABI's headquarters in Boca Raton, Fla. BIO has Cytotect...
...This quarter, BIO and partner Abbott (ABT) plan to begin a Phase III trial of Cytotect...
BioCentury | Aug 6, 2007
Clinical News

Cytotect: Phase III start

...This quarter, BIO will begin a Phase III trial of Cytotect in >20,000 pregnant women. Abbott...
...will support the trial by providing systems and tests necessary for the diagnosing CMV infection. Cytotect...
...European countries to treat CMV infection during organ transplantation. Biotest AG (FSE:BIO), Dreieich, Germany Product: Cytotect...
BioCentury | Jan 15, 2007
Clinical News

Cytotect regulatory update

...FDA granted Orphan Drug designation for Cytotect to treat cytomegalovirus (CMV) infections in pregnant women. The...
...The hyperimmunoglobulin also has Orphan Drug designation in Europe. Biotest AG (FSE:BIO), Dreieich, Germany Product: Cytotect...
Items per page:
1 - 5 of 5